IMPRIMIS PHARMACEUTICALS (IMMY) Covered Calls

You can sell covered calls on IMPRIMIS PHARMACEUTICALS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for IMMY (prices last updated Fri 4:16 PM ET):

IMPRIMIS PHARMACEUTICALS (IMMY) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
5.29 +0.58 5.22 5.29 1.6M - 0.1B
Covered Calls For IMPRIMIS PHARMACEUTICALS (IMMY)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 21 5 0.00 5.29 -5.5% -55.8%
Jan 18 5 0.45 4.84 3.3% 18.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Imprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.